VIRX Viracta Therapeutics
- 0.282
- -0.007-2.49%
- 0.278
- -0.004-1.42%
Viracta Therapeutics News
Express News | Viracta Therapeutics Shares Are Trading Lower After Leerink Partners Downgraded the Stock From Outperform to Market Perform and Lowered Its Price Target From $5 to $3
Express News | Viracta Therapeutics Inc : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $3 From $5
Viracta Therapeutics Analyst Ratings
RBC Adjusts Price Target on Viracta Therapeutics to $4 From $6, Maintains Outperform
Express News | Viracta Therapeutics Inc : RBC Cuts Target Price to $4 From $6
Viracta Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Viracta Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q2 EPS Results. Also, the Company Announced Its Phase 2 NAVAL-1 Trial Results and Will Begin a Randomized Controlled Trial (RCT)
Why Is Cancer-Focused Penny Stock Viracta Therapeutics Trading Higher On Wednesday?
Viracta Jumps After Corporate Update
Express News | Viracta Therapeutics Q2 2024 GAAP EPS $(0.25) Beats $(0.37) Estimate; Cash, Cash Equivalents, And Short-term Investments Of Approximately $30M Are Expected To Be Sufficient To Fund Operations Late Into The First Quarter Of 2025
Viracta Therapeutics 2Q Research and Development Expenses $6.5M >VIRX
Viracta Therapeutics Reported Phase 2 NAVAL-1 Trial Results From Stages 1 And 2 Of The Relapsed Or Refractory Epstein-Barr Virus-Positive Peripheral T-cell Lymphoma Cohort
Express News | Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Express News | Viracta Therapeutics Q2 EPS USD -0.25
Express News | Viracta Therapeutics Q2 Net Income USD -9.8 Million
Express News | Viracta Therapeutics Announces Positive Data From the Phase 2 Naval-1 Trial, Regulatory Progress, and Updated Nana-Val Clinical Development Plan
Express News | Viracta Therapeutics Has Received A Notice Of Allowance For Its U.S. Patent Application 18/240,853 Titled "HDAC INHIBITOR SOLID STATE FORMS (FOR THE TREATMENT OF CANCER, IMMUNE DISORDERS, AND INFLAMMATION)"
Why Digital Turbine Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Express News | On July 22, 2024, Viracta Therapeutics, Announced Workforce Reduction Affecting About 23%, To Be Completed By August 2024. The Company Anticipates Incurring Around $0.7M In Severance And Related Expenses For The Layoffs-8K
Express News | Viracta Therapeutics: Reduction in Force of About 23% of Workforce
Analysis
Price Target
No Data
